Dr. Xu currently serves as the president of ShangPharma Investment. She is a global biotech entrepreneur and drug developer, with more than 20 years of experience leading therapeutic programs and founding successful companies. She served as the founder and vice president of biology and pre-clinical services for ChemPartner, an affiliate and preferred CRO partner of ShangPharma Innovation.
Bachelors of Science, Beijing University of Chemical Technology
Master of Science, Beijing University of Chemical Technology
Ph.D in Biochemistry, Brandeis University in Massachusetts
She also was co-founder of Epimab Biotherapeutics (China). Previously, she served as director of research at Millennium Pharmaceuticals Inc., managing the small-molecule kinase inhibitor portfolios for inflammation and immunology, and was a senior scientist at Abbott Laboratories and BASF Bioresearch Corp.
Dr. Xu received her Ph.D. in Biochemistry at Brandeis University in Massachusetts and completed postdoctoral training at Harvard’s School of Public Health. She received M.S. and B.S. degrees in Chemistry from Beijing University of Chemical Technology in China. Dr. Xu is a board member of Abcuro and advisor to a number of other biotech and pharma companies including ZAI Lab Limited, ShangBay Capital and Hotspot Therapeutics.